Lifeboat Foundation

The hypertension drug rilmenidine has been shown to slow down aging in worms, an effect that in humans could hypothetically help us live longer and keep us healthier in our latter years.

Previous research has shown rilmenidine mimics the effects of caloric restriction on a cellular level. Reducing available energy while maintaining nutrition within the body has been shown to extend lifespans in several animal models.

Whether this translates to human biology, or is a potential risk to our health, is a topic of ongoing debate. Finding ways to achieve the same benefits without the costs of extreme calorie cutting could lead to new ways to improve health in old age.

MEDIA ADVISORY: An international team of researchers, led by NCI scientists, has identified 50 new areas across the human genome that are associated with the risk of developing kidney cancer.

In a new analysis of genetic susceptibility to kidney cancer, an international team of researchers has identified 50 new areas across the genome that are associated with the risk of developing kidney cancer. These insights could one day be used to advance our understanding of the molecular basis of kidney cancer, inform screening efforts for those at highest risk, and identify new drug targets. The study was led by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

A previous genome-wide association study (GWAS) of people of European ancestry identified 13 regions of the genome that are associated with kidney cancer risk. However, the study population was not diverse. To identify additional regions, researchers conducted a GWAS in participants of many different genetic ancestries that included 29,020 people with kidney cancer and 835,670 people without kidney cancer. Analysis of the data, which came from published studies, biobanks, and a new study, resulted in the identification of 50 new regions associated with the risk of developing kidney cancer, bringing the total number of such regions to 63.

Continue reading “New study provides genomic insights into kidney cancer risk” »

Technology views living cancer cell:

This technique could provide valuable insights into how different types of cancer respond to treatments. It might also help doctors understand the impact of irradiation on cells, specifically how some cancer cells resist radiation treatment. This resistance may result in relapse of the cancer.

A deeper understanding of cancer biology may lead to the development of more effective treatments in the future.

Continue reading “In a first, scientists use new tech to see inside cancer cells” »

A unique genetic mutation in two siblings – that has never been seen in anyone else – has been discovered by UK researchers at the University of Exeter, pointing the way towards new treatment options for type 1 diabetes.

The mutation is in the gene for a protein called programmed death-ligand 1 (PD-L1), and a new study explains how it may be responsible for the autoimmune form of diabetes that the children developed at a very young age.

“We searched the globe, looking at all the large-scale datasets that we know of, and we haven’t been able to find another family,” says molecular geneticist Matthew Johnson, from the University of Exeter in the UK.

A doctor has explained more about the world’s first personalised mRNA cancer jab for melanoma, which is currently being tested in British patients.

Doctor Amir Khan described the vaccine as “positive news” as he discussed how it works when he appeared on Good Morning Britain on Friday (26 April).

Dr Khan said: What is happening is the melanoma is being surgically removed and then it’s being analysed for something called neoantigens.

Hollunder et al. identify networks where deep brain stimulation reduces symptoms for Parkinson’s disease, Tourette’s syndrome, dystonia and obsessive-compulsive disorder. This revealed a fronto-rostral topography that segregates the frontal cortex.

A collaborative research team from NIMS and Tokyo University of Science has successfully developed an artificial intelligence (AI) device that executes brain-like information processing through few-molecule reservoir computing. This innovation utilizes the molecular vibrations of a select number of organic molecules.

By applying this device for the blood glucose level prediction in patients with diabetes, it has significantly outperformed existing AI devices in terms of prediction accuracy.

The work is published in the journal Science Advances.

According to a big German study, those in middle or older age today have an elevated idea of “old” compared to previous generations.” This mirrors increases in life expectancy, especially for the better-off half of the population in rich countries.

Research is finding ways to extend animal lifespans but regulators are still wary of treating ageing as a disease.

Medically, AI is helping us with everything from identifying abnormal heart rhythms before they happen to spotting skin cancer. But do we really need it to get involved with our genome? Protein-design company Profluent believes we do.

Founded in 2022 in Berkeley, California, Profluent has been exploring ways to use AI to study and generate new proteins that aren’t found in nature. This week, the team trumpeted a major success with the release of an AI-derived protein termed OpenCRISPR-1.

The protein is meant to work in the CRISPR gene-editing system, a process in which a protein cuts open a piece of DNA and repairs or replaces a gene. CRISPR has been actively in use for about 15 years, with its creators bagging the Nobel prize in chemistry in 2020. It has shown promise as a biomedical tool that can do everything from restoring vision to combating rare diseases; as an agricultural tool that can improve the vitamin D content of tomatoes, and slash the flowering time of trees from decades to months; and much more.